Annals of Clinical Microbiology, The official Journal of the Korean Society of Clinical Microbiology


Weeks in Review


Weeks to Publication
Indexed in KCI, KoreaMed, Synapse, DOAJ
Open Access, Peer Reviewed
pISSN 2288-0585 eISSN 2288-6850

Anti-Tuberculosis Drug Resistant Rates in Mycobacterium tuberculosis Isolated from Respiratory Specimens: A Multicenter Study in Korea

Original article

Annals of Clinical Microbiology (Ann Clin Microbiol) 2013 March, Volume 16, Issue 1, pages 1-7.

Anti-Tuberculosis Drug Resistant Rates in Mycobacterium tuberculosis Isolated from Respiratory Specimens: A Multicenter Study in Korea

Jayoung Kim1, Yeon-Joon Park1, Nam Yong Lee2, Chulhu L. Chang3, Miae Lee4, Jong Hee Shin5
1Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, 2Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, 3Department of Laboratory Medicine, Pusan National University Yangsan Hospital, Yangsan, 4Department of Laboratory Medicine, Ewha Womans University Mokdong Hospital, Seoul, 5Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea


Background: We analyzed the prevalence of anti-tuberculosis drug resistance in Mycobacterium tuberculosis isolates from respiratory specimens of patients with newly diagnosed and previously treated tuberculosis.

Methods: From February 2010 to July 2010, a total of 542 M. tuberculosis clinical isolates were collected from pulmonary tuberculosis patients in six university hospitals distributed throughout Korea. We analyzed the results of anti-tuberculosis drug resistance tests according to treatment history and geographic location.

Results: Among the 542 isolates, 473 (87.3%) were from newly diagnosed cases and 69 (12.7%) were from previously treated cases. The rates of multi-drug resistance (MDR), fluoroquinolone (ofloxacin, levofloxacin, and moxifloxacin) resistance, and extensive drug resistance (XDR) were 3.8%, 1.1-1.5%, and 0%, respectively, in new cases, and 21.7%, 13.0-17.4%, and 4.3%, respectively, in previously treated cases. In the previously treated cases, the proportions of XDR-TB in MDR-TB were 20% (3/15). The resistance rates were variable according to geographic location.

Conclusion: As the anti-tuberculosis drug resistance rates are much higher in newly diagnosed cases than in previously treated patients, efforts should be made to ensure that tuberculosis treatment is successful. In addition, before the selection of an anti-tuberculosis drug treatment for previously treated patients, the susceptibility test results, including to fluoroquinolone, should be verified. (Ann Clin Microbiol 2013;16:1-7)


Anti-tuberculosis drug resistant rates, Extensive drug resistance, Multi-drug resistance, Mycobacterium tuberculosis